Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: September 18, 2024
Reporting Period: Event date of September 18, 2024
Business Context: The Company is an emerging growth company incorporated in Delaware, with principal executive offices in New York, NY. The filing reports the entry into a material definitive agreement to facilitate equity financing.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed relates to the proposed capital raise:
- Proposed Offering Size: Up to $3.0 million in aggregate sales price of common stock.
- Underwriting Commission: 3.0% of gross proceeds.
- Legal Fees: Reimbursement to counsel not to exceed $75,000, plus ongoing diligence fees of $3,500 (or $7,500 under specific conditions).
- Debt and Liquidity: The filing text does not provide current debt levels, cash balances, or liquidity metrics.
Material Changes
The material change reported is the execution of an "At The Market" (ATM) Offering Agreement with Ladenburg Thalmann & Co. Inc. on September 18, 2024. This agreement allows the Company to sell shares of its common stock through the sales agent as market conditions permit. This represents a new mechanism for raising capital compared to prior periods, utilizing an existing shelf registration statement (File No. 333-264218) effective since April 20, 2022.
Guidance, Outlook, and Risks
Use of Proceeds: Net proceeds from the sale of shares are intended for working capital and general corporate purposes.
Outlook and Guidance: The filing does not provide specific financial guidance or operational outlook beyond the intent to raise capital.
Risks and Contingencies:
- Market Dependency: The Company is not obligated to make any sales; execution depends on market conditions and capital needs.
- Termination Rights: The Company may terminate the agreement with five business days' notice; the agent may terminate with two business days' notice.
- Dilution: Issuance of new shares will result in dilution to existing shareholders.
- Principal Sales: The agent may buy shares as principal, but is under no obligation to do so without a separate terms agreement.
Investor Verification Checklist
- Verify the current share price and trading volume to assess the potential dilution impact of a $3.0 million offering.
- Review the Company's most recent 10-Q or 10-K to determine current cash runway and immediate liquidity needs.
- Confirm the status of the underlying shelf registration statement (File No. 333-264218) and any remaining capacity.
- Monitor future filings for actual sales notices under the ATM agreement to track execution progress.
- Assess the impact of the 3.0% commission and legal fees on the net capital raised.